Seroatlas · Human Serome Atlas

CRISPLD2

Cysteine-rich secretory protein LCCL domain-containing 2

Also known as: CRLD2_HUMAN, DKFZP434B044, LCRISP2, LGL1

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9H0B8
Gene: CRISPLD2
Ensembl: ENSG00000103196
Chromosome: 16
Canonical length: 497 aa
Protein class: Predicted intracellular proteins, Predicted secreted proteins
Subcellular location: Vesicles
Secretome location: Secreted to blood

OverviewNCBI Gene

Predicted to enable glycosaminoglycan binding activity. Involved in face morphogenesis. Located in transport vesicle. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

497 residues, UniProt reviewed canonical sequence.

>Q9H0B8|CRISPLD2
     1  MSCVLGGVIP LGLLFLVCGS QGYLLPNVTL LEELLSKYQH NESHSRVRRA IPREDKEEIL
    61  MLHNKLRGQV QPQASNMEYM TWDDELEKSA AAWASQCIWE HGPTSLLVSI GQNLGAHWGR
   121  YRSPGFHVQS WYDEVKDYTY PYPSECNPWC PERCSGPMCT HYTQIVWATT NKIGCAVNTC
   181  RKMTVWGEVW ENAVYFVCNY SPKGNWIGEA PYKNGRPCSE CPPSYGGSCR NNLCYREETY
   241  TPKPETDEMN EVETAPIPEE NHVWLQPRVM RPTKPKKTSA VNYMTQVVRC DTKMKDRCKG
   301  STCNRYQCPA GCLNHKAKIF GTLFYESSSS ICRAAIHYGI LDDKGGLVDI TRNGKVPFFV
   361  KSERHGVQSL SKYKPSSSFM VSKVKVQDLD CYTTVAQLCP FEKPATHCPR IHCPAHCKDE
   421  PSYWAPVFGT NIYADTSSIC KTAVHAGVIS NESGGDVDVM PVDKKKTYVG SLRNGVQSES
   481  LGTPRDGKAF RIFAVRQ

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against CRISPLD2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Secreted
Secreted: Yes
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.34
Highest tissue expression: 115 nTPM

Expression across tissuesHPA

Tissue

placenta: 115 nTPM
urinary bladder: 112 nTPM
adipose tissue: 106 nTPM
endometrium: 103 nTPM
cervix: 101 nTPM
gallbladder: 97 nTPM

Single-cell type

vascular smooth muscle cells: 1,418 nCPM
pericytes: 1,352 nCPM
smooth muscle cells: 857 nCPM
fibroblasts: 765 nCPM
hepatic stellate cells: 723 nCPM
decidual stromal cells: 673 nCPM

Immune cell

neutrophil: 88 nTPM
classical monocyte: 20 nTPM
basophil: 15 nTPM
total PBMC: 4.2 nTPM
myeloid DC: 1.3 nTPM
intermediate monocyte: 1.2 nTPM

Brain region

medulla oblongata: 16 nTPM
pons: 16 nTPM
midbrain: 15 nTPM
white matter: 15 nTPM
hypothalamus: 14 nTPM
basal ganglia: 14 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.86
gnomAD pLI: 0
gnomAD missense Z: -1.6
DepMap mean gene effect: 0
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads CRISPLD2 as an antibody target. Whether an autoantibody or antibody against CRISPLD2 could matter depends on whether native CRISPLD2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

CRISPLD2 is annotated as secreted, so native CRISPLD2 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label CRISPLD2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...